GREENWOOD VILLAGE, Colo., April 22 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc., today announced that it has entered into a letter of intent (LOI) to acquire DMI Biosciences, Inc. This acquisition will give AMPIO access to all rights, royalties and patents associated with a drug that treats premature ejaculation (P.E.) recently licensed to a specialty pharmaceutical company after demonstrating safety and efficacy in a Phase II clinical trial. This P.E. drug is protected by multiple U.S. and International patents, and is currently undergoing Phase III clinical trials in Europe.
